WO2016190570A3 - Method for manufacturing core-shell type sustained-release pellets containing dipyridamole as active ingredient - Google Patents

Method for manufacturing core-shell type sustained-release pellets containing dipyridamole as active ingredient Download PDF

Info

Publication number
WO2016190570A3
WO2016190570A3 PCT/KR2016/004845 KR2016004845W WO2016190570A3 WO 2016190570 A3 WO2016190570 A3 WO 2016190570A3 KR 2016004845 W KR2016004845 W KR 2016004845W WO 2016190570 A3 WO2016190570 A3 WO 2016190570A3
Authority
WO
WIPO (PCT)
Prior art keywords
shell type
active ingredient
release pellets
type sustained
manufacturing core
Prior art date
Application number
PCT/KR2016/004845
Other languages
French (fr)
Korean (ko)
Other versions
WO2016190570A2 (en
Inventor
이준용
Original Assignee
초당약품공업 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 초당약품공업 주식회사 filed Critical 초당약품공업 주식회사
Publication of WO2016190570A2 publication Critical patent/WO2016190570A2/en
Publication of WO2016190570A3 publication Critical patent/WO2016190570A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a method for manufacturing core-shell type sustained-release pellets containing dipyridamole as an active ingredient. More specifically, the present invention relates to a method for manufacturing core-shell type sustained-release pellets using tartaric acid crystals as a core component and containing dipyridamole and a sustained- and controlled-release polymer as shell components.
PCT/KR2016/004845 2015-05-22 2016-05-10 Method for manufacturing core-shell type sustained-release pellets containing dipyridamole as active ingredient WO2016190570A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150071452A KR101767450B1 (en) 2015-05-22 2015-05-22 Process for preparing core-shell sustained release pellet including dipyridamole as active ingredient
KR10-2015-0071452 2015-05-22

Publications (2)

Publication Number Publication Date
WO2016190570A2 WO2016190570A2 (en) 2016-12-01
WO2016190570A3 true WO2016190570A3 (en) 2017-01-19

Family

ID=57393924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/004845 WO2016190570A2 (en) 2015-05-22 2016-05-10 Method for manufacturing core-shell type sustained-release pellets containing dipyridamole as active ingredient

Country Status (2)

Country Link
KR (1) KR101767450B1 (en)
WO (1) WO2016190570A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080052011A (en) * 2006-12-07 2008-06-11 보령제약 주식회사 Oral administrative dosage form for treating cardiovascular system disease
US20100080846A1 (en) * 2008-09-25 2010-04-01 Avshalom Ben-Menachem Dipyridamole and acetylsalicylic acid formulations and process for preparing same
US20120087979A1 (en) * 2010-10-07 2012-04-12 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
KR20120105317A (en) * 2011-03-15 2012-09-25 보령제약 주식회사 A combined formulation with improved stability
KR20140088230A (en) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 Drug delivery systems comprising weakly basic drugs and organic acids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140088230A (en) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 Drug delivery systems comprising weakly basic drugs and organic acids
KR20080052011A (en) * 2006-12-07 2008-06-11 보령제약 주식회사 Oral administrative dosage form for treating cardiovascular system disease
US20100080846A1 (en) * 2008-09-25 2010-04-01 Avshalom Ben-Menachem Dipyridamole and acetylsalicylic acid formulations and process for preparing same
US20120087979A1 (en) * 2010-10-07 2012-04-12 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
KR20120105317A (en) * 2011-03-15 2012-09-25 보령제약 주식회사 A combined formulation with improved stability

Also Published As

Publication number Publication date
KR101767450B1 (en) 2017-08-11
KR20160136998A (en) 2016-11-30
WO2016190570A2 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
HUE054690T2 (en) 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl substituted compounds as hiv inhibitors
WO2016154583A3 (en) Amino acid animal feed composition
MX2016004012A (en) Feed pellets and related systems and methods.
IL270134B (en) Process for preparing optically active 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds
WO2012106303A1 (en) Pharmaceutical formulations including an amine compound
WO2015040410A3 (en) Additive manufacturing method
WO2015105750A3 (en) Processes for preparing metallocene-based catalyst systems
WO2016159577A3 (en) 1,2-naphthoquinone derivative and method for preparing same
EP3674278A4 (en) Sustained-release and controlled-release fertilizer having core-shell structure and preparation method therefor
EP3007684B8 (en) A process for producing microcapsules comprising an active component encapsulated, protected and stabilised within a protein shell
WO2018105865A8 (en) Catalyst composition for synthesizing olefin copolymer, and method for preparing olefin copolymer
WO2016001937A3 (en) Modified release pharmaceutical preparations
EP3351548A4 (en) Crosslinked nucleic acid guna, method for producing same, and intermediate compound
WO2014009370A3 (en) Core-shell capsules and methods for encapsulation including diffusion through spherical capsule membranes
WO2014099809A3 (en) Audio burst collision resolution
EP3392299A4 (en) Porous film, method for manufacturing porous film, microlens array, microreactor, and bio-device
WO2014179567A3 (en) Methods and compositions for treating beta-thalassemia and sickle cell disease
WO2016193924A3 (en) System of multiple bags and method for the preparation of hemocomponents
WO2017013498A3 (en) Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions
MX2019012454A (en) Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin- 2-yl)-1h-pyrazol-5-ol hydrochloride.
WO2018093223A3 (en) Method for preparing eldecalcitol and intermediate therefor
EP3677684A4 (en) Method for producing fulvic acid solution, and fulvic acid solution
EP3483936A4 (en) Semiconductor storage element, other elements, and method for manufacturing same
EP3476806A4 (en) Solution, method for producing same, and method for producing secondary battery active substance
WO2017116113A3 (en) Electrode, method for manufacturing electrode, and fuel cell including electrode

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16800210

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16800210

Country of ref document: EP

Kind code of ref document: A2